Table 1

Characteristics of HBO-treated patients and outcome of HBO

Patient

Sex

Age(years)

Symptom duration (years)

Bladder capacity on FVC (ml)

Times of hydrodistension before HBO

Sessions of HBO treatment

Response to HBO

PBS/IC subtype based on hydrodistension

Observation duration after HBO (months)


1*

female

79

2.2

40

2

20

Responder

Ulcerative

50


2*

female

61

4.5

60

2

20

Responder

Ulcerative

44


3

female

28

1.8

80

1

10

Non-responder

Non-ulcerative

4


4

female

68

2.4

70

4

10

Responder

Ulcerative

33


5

female

57

3.6

80

4

10

Responder

Ulcerative

15


6

male

65

4

50

2

20

Non-responder

Non-ulcerative

30


7

female

70

3.2

100

1

10

Responder

Ulcerative

14


8

female

50

2.1

90

2

10

Non-responder

Non-ulcerative

4


9

female

70

6.4

40

6

10

Responder

Ulcerative

13


10

female

43

3.5

120

1

10

Non-responder

Ulcerative

3


11

female

70

3.2

50

4

10

Responder

Ulcerative

12


*Two patients of case 1, 2 underwent additional 10 sessions after 13, 14 months, respectively.

Tanaka et al. BMC Urology 2011 11:11   doi:10.1186/1471-2490-11-11

Open Data